Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of ASA404 and docetaxel for non small cell lung cancer that has continued to grow during chemotherapy or has come back after treatment (ATTRACT 2)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was looking at a drug called ASA404 in combination with the chemotherapy drug docetaxel for non small cell lung cancer (NSCLC) that was stage 3B or 4.
Doctors often use chemotherapy to treat NSCLC that is
Cancer cells need a blood supply to help them grow and survive. Growing cancer cells can encourage the growth of new blood vessels. This is called angiogenesis.
In this trial, researchers were looking at a drug called ASA404 which targets the cancer’s blood supply and might have helped to stop the cancer growing. They compared ASA404 with a dummy drug (a
- Find out if ASA404 worked better than the dummy drug, when you have it with docetaxel for NSCLC that had continued to grow during chemotherapy or had come back after treatment
- Learn more about the side effects and how they affected people’s quality of life
Summary of results
The trial recruited 920 people who had non small cell lung cancer that was stage 3B or stage 4. Everybody taking part had already had chemotherapy, but their cancer had continued to grow or had come back after treatment.
- 460 people had docetaxel and ASA404
- 460 people had docetaxel and a dummy drug (placebo)
The researchers found that
- The number of people whose cancer responded to the treatment was about the same in both groups
- On average, the length of time people lived after treatment was about the same in both groups
- The side effects were also similar in both groups
The trial team concluded that in this study, ASA404 did not work any better than the dummy drug and the trial was stopped early. There will not be any further trials planned for this drug.
We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Dr Rohit Lal